Continue to site >
Trending ETFs

Name

Price

Aum/Mkt Cap

YIELD & DIV

Exp Ratio

Watchlist

$74.38

$4.95 B

1.01%

$0.75

0.81%

Vitals

YTD Return

4.2%

1 yr return

17.9%

3 Yr Avg Return

13.3%

5 Yr Avg Return

14.5%

Net Assets

$4.95 B

Holdings in Top 10

28.9%

52 WEEK LOW AND HIGH

$73.6
$66.12
$78.28

Expenses

OPERATING FEES

Expense Ratio 0.81%

SALES FEES

Front Load N/A

Deferred Load N/A

TRADING FEES

Turnover 43.00%

Redemption Fee N/A


Min Investment

Standard (Taxable)

$2,500

IRA

N/A


Fund Classification

Fund Type

Open End Mutual Fund

Investment Style

Health


Name

Price

Aum/Mkt Cap

YIELD & DIV

Exp Ratio

Watchlist

$74.38

$4.95 B

1.01%

$0.75

0.81%

JNGLX - Profile

Distributions

  • YTD Total Return 4.2%
  • 3 Yr Annualized Total Return 13.3%
  • 5 Yr Annualized Total Return 14.5%
  • Capital Gain Distribution Frequency Annually
  • Net Income Ratio 0.87%
DIVIDENDS
  • Dividend Yield 1.0%
  • Dividend Distribution Frequency Semi-Annually

Fund Details

  • Legal Name
    Janus Henderson Global Life Sciences Fund
  • Fund Family Name
    Janus Henderson
  • Inception Date
    Dec 31, 1998
  • Shares Outstanding
    N/A
  • Share Class
    D
  • Currency
    USD
  • Domiciled Country
    United States
  • Manager
    Andrew Acker

Fund Description

The fund pursues its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that the portfolio managers believe have a life science orientation. In the fund's pursuit of companies with a life science orientation, the fund has a fundamental policy to normally invest at least 25% of its total assets in securities of companies that are categorized in the "life sciences" sector.


JNGLX - Performance

Return Ranking - Trailing

Period JNGLX Return Category Return Low Category Return High Rank in Category (%)
YTD 4.2% -80.8% 25.3% 67.76%
1 Yr 17.9% -28.4% 77.3% 52.26%
3 Yr 13.3%* -0.1% 33.4% 26.35%
5 Yr 14.5%* 2.1% 32.2% 34.97%
10 Yr 19.3%* 9.8% 21.9% 14.52%

* Annualized

Return Ranking - Calendar

Period JNGLX Return Category Return Low Category Return High Rank in Category (%)
2020 16.4% -13.6% 178.2% 39.31%
2019 21.5% 3.8% 63.8% 44.83%
2018 -7.9% -49.7% 21.5% 58.39%
2017 21.1% -59.8% 54.4% 37.78%
2016 -13.4% -36.6% 11.6% 42.97%

Total Return Ranking - Trailing

Period JNGLX Return Category Return Low Category Return High Rank in Category (%)
YTD 4.2% -80.8% 25.3% 67.76%
1 Yr 17.9% -30.4% 77.3% 50.90%
3 Yr 13.3%* -15.9% 33.4% 28.49%
5 Yr 14.5%* -7.4% 32.2% 28.16%
10 Yr 19.3%* 9.8% 21.9% 13.43%

* Annualized

Total Return Ranking - Calendar

Period JNGLX Return Category Return Low Category Return High Rank in Category (%)
2020 16.4% -13.6% 178.2% 39.31%
2019 21.5% 3.8% 63.8% 44.83%
2018 -7.9% -25.3% 22.2% 64.23%
2017 22.6% -10.8% 54.4% 34.81%
2016 -13.1% -36.6% 11.6% 56.25%

NAV & Total Return History


JNGLX - Holdings

Concentration Analysis

JNGLX Category Low Category High JNGLX % Rank
Net Assets 4.95 B 238 K 50.5 B 14.69%
Number of Holdings 147 11 477 11.81%
Net Assets in Top 10 1.46 B 2.18 K 21.1 B 10.55%
Weighting of Top 10 28.89% 8.6% 94.7% 87.76%

Top 10 Holdings

  1. AstraZeneca PLC 4.48%
  2. AstraZeneca PLC 4.48%
  3. AstraZeneca PLC 4.48%
  4. AstraZeneca PLC 4.48%
  5. AstraZeneca PLC 4.48%
  6. AstraZeneca PLC 4.48%
  7. AstraZeneca PLC 4.48%
  8. AstraZeneca PLC 4.48%
  9. AstraZeneca PLC 4.48%
  10. AstraZeneca PLC 4.48%

Asset Allocation

Weighting Return Low Return High JNGLX % Rank
Stocks
94.99% 83.68% 101.79% 92.41%
Other
4.21% -24.25% 9.11% 1.27%
Cash
0.80% -0.82% 10.99% 38.40%
Preferred Stocks
0.00% 0.00% 6.25% 30.80%
Convertible Bonds
0.00% 0.00% 0.10% 23.63%
Bonds
0.00% 0.00% 15.36% 27.43%

Stock Sector Breakdown

Weighting Return Low Return High JNGLX % Rank
Healthcare
99.87% 63.33% 100.00% 44.30%
Financial Services
0.08% 0.00% 1.92% 21.52%
Basic Materials
0.04% 0.00% 8.13% 24.47%
Utilities
0.00% 0.00% 1.14% 23.63%
Technology
0.00% 0.00% 19.13% 30.38%
Real Estate
0.00% 0.00% 6.13% 27.43%
Industrials
0.00% 0.00% 7.02% 28.27%
Energy
0.00% 0.00% 0.80% 23.63%
Communication Services
0.00% 0.00% 7.81% 26.16%
Consumer Defense
0.00% 0.00% 28.21% 29.96%
Consumer Cyclical
0.00% 0.00% 16.95% 31.22%

Stock Geographic Breakdown

Weighting Return Low Return High JNGLX % Rank
US
76.84% 57.23% 100.70% 79.75%
Non US
18.15% 0.00% 42.77% 28.27%

JNGLX - Expenses

Operational Fees

JNGLX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 0.81% 0.08% 2.91% 41.88%
Management Fee 0.64% 0.00% 1.25% 49.72%
12b-1 Fee N/A 0.00% 1.00% N/A
Administrative Fee 0.12% 0.03% 0.25% 44.90%

Sales Fees

JNGLX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load N/A 0.00% 5.75% N/A
Deferred Load N/A 1.00% 5.00% N/A

Trading Fees

JNGLX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A 1.00% 2.00% 4.88%

Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

JNGLX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover 43.00% 0.00% 256.00% 43.03%

JNGLX - Distributions

Dividend Yield Analysis

JNGLX Category Low Category High JNGLX % Rank
Dividend Yield 1.01% 0.00% 2.44% 26.89%

Dividend Distribution Analysis

JNGLX Category Low Category High Category Mod
Dividend Distribution Frequency Semi-Annually Annually Semi-Annually Semi-Annually

Net Income Ratio Analysis

JNGLX Category Low Category High JNGLX % Rank
Net Income Ratio 0.87% -2.54% 1.92% 12.64%

Capital Gain Distribution Analysis

JNGLX Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Annually Semi-Annually Annually

Dividend Payout History

View More +

JNGLX - Fund Manager Analysis

Managers

Andrew Acker


Start Date

Tenure

Tenure Rank

May 01, 2007

14.43

14.4%

Andy Acker is a Portfolio Manager at Janus Henderson Investors responsible for managing the Global Life Sciences and Biotechnology strategies since 2007 and 2018, respectively. He also leads the firm’s Health Care Sector Research Team. Andy was assistant portfolio manager on the Global Life Sciences strategy from 2003 to 2007. He joined Janus in 1999 as a research analyst focused on companies in the biotechnology and pharmaceutical industries. Prior to this, he worked as a strategy consultant for the Boston Consulting Group and as a health care analyst for Morgan Stanley Venture Partners. Andy received his bachelor of science degree in biochemical sciences from Harvard University, graduating magna cum laude and Phi Beta Kappa. He also earned an MBA with honours from Harvard Business School. Andy holds the Chartered Financial Analyst designation and has 23 years of financial industry experience.

Tenure Analysis

Category Low Category High Category Average Category Mode
0.03 24.06 6.71 1.46